Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
NCI-CCC Tumor Board Question
•
NCI-CCC Lymphoma Tumor Board Question
•
City of Hope
How would you manage a patient with a recent diagnosis of advanced DLBCL (non-GCB subtype) who has baseline grade 3 neuropathy?
Answer from: Medical Oncologist at Community Practice
Avoid neurotoxic agents. Substitute pola; avoid vincristine.
Sign In
or
Register
to read more
30982
Related Questions
In light of data from TRIANGLE, ECHO, and ENRICH, what is the best strategy to treat newly diagnosed patients with the blastoid variant MCL?
How would you manage a frail patient with GCB DLBCL who is unable to complete R-CHOP but has moderate residual disease?
How would you manage a patient with marginal zone lymphoma who progress after treatment on a BKTI?
What is the role of surveillance imaging after first line therapy in patients with aggressive lymphomas?
Is there a role for thiotepa-based auto transplant for consolidation in PCNSL if the patient had progression on both MTX and Ara-C?
How would you structure your monitoring for a low-risk leukemic TP53-negative mantle cell lymphoma with 5% MCL cells detected in both peripheral blood and bone marrow, mild splenomegaly, and no lymphadenopathy or B symptoms?
For a patient with a metastatic solid tumor in remission on a checkpoint inhibitor who also has R/R multiple myeloma, would you feel comfortable with a bispecific T-cell engager antibody?
Has the data for the ENRICH study changed your practice for the initial treatment of mantle-cell lymphoma?
How would you approach adjusting nivo+AVD therapy for advanced Hodgkin lymphoma if a patient develops treatment limited immunotherapy toxicity?
If you are using talquetamab as bridging before BCMA CAR-T therapy, when do you assess for response and/or stop the talquetamab? Do you routinely extend the talquetamab until 1-2 weeks before lymphodepletion, or do you stop earlier if response is achieved?